Stocks and Investing
Stocks and Investing
Thu, March 9, 2017
[ 11:45 AM ] - WOPRAI
[ 11:45 AM ] - WOPRAI
[ 11:45 AM ] - WOPRAI
[ 11:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 09:45 AM ] - WOPRAI
[ 07:47 AM ] - WOPRAI
[ 07:47 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 04:45 AM ] - WOPRAI
[ 01:46 AM ] - WOPRAI
[ 01:46 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
[ 01:45 AM ] - WOPRAI
David Nierengarten Reiterated (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017
David Nierengarten of Wedbush, Reiterated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $28 on, Mar 9th, 2017.
David has made no other calls on ANAB in the last 4 months.
There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Kennen MacKay of "Credit Suisse" Initiated at Buy and Held Target at $34 on, Tuesday, February 21st, 2017